Is NCT02882009 results overdue?

Yes — results are overdue. Primary completion was 2017-03-22; the FDAAA-801 reporting deadline (2018-03-22) passed 3013 days ago and no results are posted on ClinicalTrials.gov.

A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy Participants

NCT ID	NCT02882009 ↗
Sponsor	Hoffmann-La Roche (INDUSTRY)
Phase	PHASE1
Status	COMPLETED
Primary completion	2017-03-22 (ACTUAL)
Reporting deadline	2018-03-22 (completion + 365d)
Days overdue	3013
Results posted	No — check results tab ↗
FDA-regulated	drug: yes, device: no
Provenance	Flagged overdue on 2026-06-21 · SHA-256 `0b94f05b5b3a5ef7…` (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02882009. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.